These results demonstrated that constitutive activation of the PI3K pathway is necessary for the survival of AML blasts and that targeting of this pathway with pharmacologic inhibitors may be of clinical benefit in treatment of AML [325]. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.